Payment overview · 2025
General Payments
$1,972.05
101 reported records · 23 companies
Healthcare provider profile · identity verified
Matthew Selman Walker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WALKER, LA · NPI 1023336724
Verified facts
What the public records show
CMS Open Payments records show Matthew Selman Walker, M.D. received $1,972.05 in general payments during 2025 across 101 reported records.
AstraZeneca Pharmaceuticals LP accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 241 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 320 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Soliqua 100-33 by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $259.68 | 13.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $211.62 | 10.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $201.88 | 10.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.13 | 9.6% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $178.14 | 9.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $149.19 | 7.6% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.26 | 6.3% | 8 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $112.82 | 5.7% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.73 | 4.0% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $63.49 | 3.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $55.08 | 2.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.40 | 2.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $48.38 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.17 | 2.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.46 | 2.1% | 2 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $28.66 | 1.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.17 | 1.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.80 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.44 | 1.0% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $16.97 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.01 | 0.8% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.06 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.51 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,972.05 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $193.16 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $151.36 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $151.36 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $142.95 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $127.99 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.61 | 3 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $119.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $112.82 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $106.22 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.27 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $95.27 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.73 | 5 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $63.49 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.14 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.45 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $55.08 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.40 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.52 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $48.38 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.77 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.49 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.98 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $35.19 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $28.66 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.17 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 23 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 30 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 108 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 241 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 320 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 148 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
148 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
108 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
241 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
133 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
320 | 61 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 262 |
| Amlodipine Besylate | Amlodipine Besylate | 697 | 183 |
| Pantoprazole Sodium | Pantoprazole Sodium | 518 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 119 |
| Lisinopril | Lisinopril | 453 | 119 |
| Gabapentin | Gabapentin | 372 | 100 |
| Carvedilol | Carvedilol | 329 | 79 |
| Ozempic | Semaglutide | 320 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 80 |
| Trazodone Hcl | Trazodone Hcl | 279 | 69 |
| Metformin Hcl | Metformin Hcl | 275 | 80 |
| Sertraline Hcl | Sertraline Hcl | 266 | 66 |
| Mounjaro | Tirzepatide | 241 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 67 |
| Omeprazole | Omeprazole | 226 | 64 |
| Metformin Hcl Er | Metformin Hcl | 214 | 58 |
| Losartan Potassium | Losartan Potassium | 190 | 57 |
| Meloxicam | Meloxicam | 175 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 39 |
| Alprazolam | Alprazolam | 153 | 28 |
| Ezetimibe | Ezetimibe | 148 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 148 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 146 | 41 |
| Trulicity | Dulaglutide | 133 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 129 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 39 |
| Furosemide | Furosemide | 120 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 41 |
| Jardiance | Empagliflozin | 108 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 37 |
| Montelukast Sodium | Montelukast Sodium | 88 | 21 |
| Alendronate Sodium | Alendronate Sodium | 84 | 24 |
| Synthroid | Levothyroxine Sodium | 84 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 18 |
| Buspirone Hcl | Buspirone Hcl | 82 | 18 |
| Allopurinol | Allopurinol | 79 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 25 |
| Simvastatin | Simvastatin | 71 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Finasteride | Finasteride | 66 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 14 |
| Spironolactone | Spironolactone | 61 | 20 |
| Mirtazapine | Mirtazapine | 59 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 12 |
| Potassium Chloride | Potassium Chloride | 57 | 13 |
| Ondansetron Odt | Ondansetron | 56 | 20 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 16 |
| Clonidine Hcl | Clonidine Hcl | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 12 |
| Tramadol Hcl | Tramadol Hcl | 45 | 18 |
| Bupropion Xl | Bupropion Hcl | 43 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 42 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 41 | suppressed |
| Famotidine | Famotidine | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Eliquis | Apixaban | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Naproxen | Naproxen | 37 | 15 |
| Vraylar | Cariprazine Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 18 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Prednisone | Prednisone | 25 | 21 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Valsartan | Valsartan | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,972.05 · 101 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, JATENZO, Kerendia, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, Symbravo, TEZSPIRE, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, Xelstrym, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error